Brief: Aptevo Therapeutics Announces H1 2024 Plan For Development Of Lead Candidate APVO436 For Treatment Of Frontline Acute Myeloid Leukemia

Aptevo Therapeutics

05/03/2024 14:58

March 5 (Reuters) - Aptevo Therapeutics Inc  APVO.O :
    * APTEVO THERAPEUTICS INC: ANNOUNCES 1H24 PLAN FOR
DEVELOPMENT OF
LEAD CANDIDATE APVO436 FOR THE TREATMENT OF FRONTLINE ACUTE
MYELOID LEUKEMIA
    * APTEVO THERAPEUTICS INC - ALG.APV-527 PHASE 1 TRIAL FOR
THE
TREATMENT OF MULTIPLE SOLID TUMORS CONTINUES ENROLLMENT, INTERIM
RESULTS EXPECTED 1H24
    * APTEVO THERAPEUTICS INC: APVO436 INTERIM RESULTS EXPECTED
LATE
2H24
    * APTEVO THERAPEUTICS INC - APTEVO HAD CASH AND CASH
EQUIVALENTS
AS OF DECEMBER 31, 2023, TOTALING $16.9 MILLION

Source text for Eikon:  ID:n0000950170-24-025427 
Further company coverage:  APVO.O 

 ((Reuters.Briefs@thomsonreuters.com;))